𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A brief history of pediatric oncology in Porto, Portugal

✍ Scribed by Borges, B.P. Sodr�

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
71 KB
Volume
39
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Natural history of histiocytosis X: A pe
Natural history of histiocytosis X: A pediatric oncology group study
✍ Berry, D. H. ;Gresik, Mary V. ;Humphrey, G. Bennett ;Starling, Kenneth ;Vietti, 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 485 KB

The best therapy for patients with histiocytosis X with disease involvement other than isolated bone lesions but without organ dysfunction is unclear. This retrospective study was undertaken to define the natural history of this group of patients. In 25 of the 92 studied patients, there was no prog

Outbreak of varicella in a pediatric onc
Outbreak of varicella in a pediatric oncology unit
✍ Kavaliotis, John; Loukou, Ioanna; Trachana, Matia; Gombakis, Nick; Tsagaropoulou 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 3 views

Background. Varicella-zoster virus (VZV) infection is usually benign but immunocompromised patients are at great risk for visceral dissemination and fatal outcome. During a nationwide varicella outbreak, several of our patients contracted the disease. We undertook studies of the epidemiology and the

Phase I trial of trimetrexate in pediatr
Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study
✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma